2.要約中間連結財務諸表及び主な注記
(1)要約中間連結財政状態計算書
| | | | | (単位:百万円) |
| | | 前連結会計年度末 (2026年3月31日) | | 当中間連結会計期間末 (2026年9月30日) |
資産 | | | | | |
流動資産 | | | | | |
現金及び現金同等物 | | | 76,592 | | 72,849 |
営業債権及びその他の債権 | | | 46,157 | | 48,462 |
棚卸資産 | | | 51,595 | | 53,251 |
その他の金融資産 | | | 2,414 | | 2,750 |
その他の流動資産 | | | 6,326 | | 6,769 |
流動資産合計 | | | 183,086 | | 184,083 |
非流動資産 | | | | | |
有形固定資産 | | | 34,954 | | 35,705 |
無形資産 | | | 48,242 | | 53,990 |
使用権資産 | | | 2,588 | | 3,336 |
その他の金融資産 | | | 67,356 | | 48,713 |
繰延税金資産 | | | 6,957 | | 6,957 |
その他の非流動資産 | | | 3,172 | | 3,102 |
非流動資産合計 | | | 163,272 | | 151,806 |
資産合計 | | | 346,359 | | 335,890 |
| | | | | |
| | | | | (単位:百万円) |
| | | 前連結会計年度末 (2026年3月31日) | | 当中間連結会計期間末 (2026年9月30日) |
負債及び資本 | | | | | |
負債 | | | | | |
流動負債 | | | | | |
営業債務及びその他の債務 | | | 26,132 | | 24,311 |
その他の金融負債 | | | 273 | | 302 |
リース負債 | | | 913 | | 1,406 |
未払法人所得税 | | | 6,979 | | 4,257 |
その他の流動負債 | | | 7,806 | | 8,169 |
流動負債合計 | | | 42,105 | | 38,447 |
非流動負債 | | | | | |
その他の金融負債 | | | 235 | | 235 |
リース負債 | | | 1,654 | | 1,921 |
退職給付に係る負債 | | | 4,557 | | 4,215 |
繰延税金負債 | | | 5,875 | | 265 |
その他の非流動負債 | | | 59 | | 57 |
非流動負債合計 | | | 12,382 | | 6,695 |
負債合計 | | | 54,488 | | 45,142 |
資本 | | | | | |
資本金 | | | 5,174 | | 5,174 |
資本剰余金 | | | 4,547 | | 4,568 |
利益剰余金 | | | 246,691 | | 258,162 |
自己株式 | | | △2,440 | | △2,422 |
その他の資本の構成要素 | | | 37,578 | | 24,943 |
親会社の所有者に帰属する持分合計 | | | 291,551 | | 290,426 |
非支配持分 | | | 319 | | 321 |
資本合計 | | | 291,871 | | 290,747 |
負債及び資本合計 | | | 346,359 | | 335,890 |
E0093145160日本新薬株式会社Nippon Shinyaku Co.,Ltd.四半期第7号参考様式 [IFRS](連結)(一般2Q)IFRStrueCTE2026-04-012026-09-30HY2027-03-312025-04-012025-09-302026-03-311falsefalsefalse451602025-04-012025-09-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602025-04-012025-09-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602025-04-012025-09-30jpigp_cor:NonControllingInterestsIFRSMember451602025-09-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602025-09-30jpigp_cor:ShareCapitalIFRSMember451602025-09-30jpigp_cor:CapitalSurplusIFRSMember451602025-09-30jpigp_cor:RetainedEarningsIFRSMember451602025-09-30jpigp_cor:TreasurySharesIFRSMember451602025-09-30jpigp_cor:OtherComponentsOfEquityIFRSMember451602025-09-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602025-09-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602025-09-30jpigp_cor:NonControllingInterestsIFRSMember451602026-04-012026-09-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602026-04-012026-09-30jpigp_cor:ShareCapitalIFRSMember451602026-04-012026-09-30jpigp_cor:CapitalSurplusIFRSMember451602026-04-012026-09-30jpigp_cor:RetainedEarningsIFRSMember451602026-04-012026-09-30jpigp_cor:TreasurySharesIFRSMember451602026-04-012026-09-30jpigp_cor:OtherComponentsOfEquityIFRSMember451602026-04-012026-09-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602026-04-012026-09-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602026-04-012026-09-30jpigp_cor:NonControllingInterestsIFRSMember451602026-09-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602026-09-30jpigp_cor:ShareCapitalIFRSMember451602026-09-30jpigp_cor:CapitalSurplusIFRSMember451602026-09-30jpigp_cor:RetainedEarningsIFRSMember451602026-09-30jpigp_cor:TreasurySharesIFRSMember451602026-09-30jpigp_cor:OtherComponentsOfEquityIFRSMember451602026-09-30jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602026-09-30jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602026-09-30jpigp_cor:NonControllingInterestsIFRSMember451602025-04-012025-09-30jpcrp_cor:ReportableSegmentsMember451602025-04-012025-09-30tse-scediffr-45160:MedicineReportableSegmentMember451602025-04-012025-09-30tse-scediffr-45160:FunctionalFoodsReportableSegmentMember451602025-04-012025-09-30jpcrp_cor:ReconcilingItemsMember451602026-04-012026-09-30tse-scediffr-45160:MedicineReportableSegmentMember451602026-04-012026-09-30tse-scediffr-45160:FunctionalFoodsReportableSegmentMember451602026-04-012026-09-30jpcrp_cor:ReconcilingItemsMember451602026-04-012026-09-30jpcrp_cor:ReportableSegmentsMember451602025-03-31451602026-03-31451602025-04-012025-09-30451602025-09-30451602026-04-012026-09-30451602026-09-30451602026-11-13451602025-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602025-03-31jpigp_cor:ShareCapitalIFRSMember451602025-03-31jpigp_cor:CapitalSurplusIFRSMember451602025-03-31jpigp_cor:RetainedEarningsIFRSMember451602025-03-31jpigp_cor:TreasurySharesIFRSMember451602025-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember451602025-03-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602025-03-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602025-03-31jpigp_cor:NonControllingInterestsIFRSMember451602026-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602026-03-31jpigp_cor:ShareCapitalIFRSMember451602026-03-31jpigp_cor:CapitalSurplusIFRSMember451602026-03-31jpigp_cor:RetainedEarningsIFRSMember451602026-03-31jpigp_cor:TreasurySharesIFRSMember451602026-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember451602026-03-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember451602026-03-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember451602026-03-31jpigp_cor:NonControllingInterestsIFRSMember451602025-04-012025-09-30jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember451602025-04-012025-09-30jpigp_cor:ShareCapitalIFRSMember451602025-04-012025-09-30jpigp_cor:CapitalSurplusIFRSMember451602025-04-012025-09-30jpigp_cor:RetainedEarningsIFRSMember451602025-04-012025-09-30jpigp_cor:TreasurySharesIFRSMember451602025-04-012025-09-30jpigp_cor:OtherComponentsOfEquityIFRSMemberiso4217:JPYxbrli:pureiso4217:JPYxbrli:shares